Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 2/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904514 | 0.85 | HTR2A (0.50) | METAP1AHRCMA1HTR2AHTR2C | |
| SCHEMBL588130 | 0.85 | CYP2A6 (0.54) | METAP1CYP1A2AHRCMA1HTR2A | |
| SCHEMBL3269917 | 0.85 | CYP2A6 (0.54) | METAP1CYP1A2AHRCMA1HTR2A | |
| SCHEMBL30748374 | 0.85 | CYP2A6 (0.54) | METAP1CYP1A2AHRCMA1HTR2A | |
| Bromide SCHEMBL189011 | 0.82 | — | — | |
| Ammonia Solution, Strong SCHEMBL1325642 | 0.82 | — | — | |
| SCHEMBL5143608 | 0.81 | HTR2A (0.46) | METAP1AHRCMA1HTR2AHTR2C | |
| SCHEMBL12430509 | 0.81 | HTR2A (0.46) | METAP1CYP1A2AHRCMA1HTR2A | |
| Hydrochloric Acid SCHEMBL8894992 | 0.80 | HTR2A (0.46) | METAP1AHRCMA1HTR2AHTR2C | |
| SCHEMBL10463438 | 0.79 | AHR (0.50) | METAP1CYP1A2AHRCMA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590087-B2 | Inhibiting USP36 | VALO HEALTH, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| CN-114222574-B | Inhibition of USP36 | 瓦洛健康股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-20230381132-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| US-20230381132-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| US-20230381132-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-11-30 | — | — | US | disclosed |
| EP-3337497-B1 | COMPOSITION AND METHODS OF USE OF NOVEL PHENYLALANINE SMALL ORGANIC COMPOUNDS TO DIRECTLY MODULATE PCSK9 PROTEIN ACTIVITY | SRX CARDIO LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220213088-A1 | INHIBITING USP36 | Valo Health, LLC | 2022-07-07 | — | — | US | disclosed |
| US-20220213088-A1 | INHIBITING USP36 | Valo Health, LLC | 2022-07-07 | — | — | US | disclosed |
| EP-0861837-A1 | 2-Aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-09-02 | — | — | EP | disclosed |
| EP-0137333-B1 | SPIRO-TRICYCLICAROMATIC SUCCINIMIDE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE | ALCON LABORATORIES, INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-5153211-A | Enzyme inhibitors | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5070100-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1991-12-03 | — | — | US | disclosed |
| US-4864028-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1989-09-05 | — | — | US | disclosed |
| US-4537892-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0137333-A2 | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | ALCON LABORATORIES, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
| US-4217302-A | INSECTICIDES, MITICIDES | ZOECON CORPORATION (US) | 1980-08-12 | — | — | US | disclosed |
| US-4192888-A | Pharmaceutical compositions and method of inhibiting phenylethanolamine N-methyltransferase | SMITHKLINE CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
| US-4189598-A | INSECTICIDES., MITICIDE | ZOECON CORPORATION (US) | 1980-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381132-A1 | NOVEL COMPOUNDS | CNKSR1, RORC, RCOR3 | METAP1 2540/4885CYP1A2 355/4885AHR 735/4885 |
| US-20220213088-A1 | INHIBITING USP36 | USP36, USP30, USP39 | METAP1 2578/4885CYP1A2 3442/4885AHR 3113/4885 |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | METAP1 3538/4885CYP1A2 408/4885AHR 2351/4885 |
| US-12590087-B2 | Inhibiting USP36 | USP36, USP39, USP30 | METAP1 3316/4885CYP1A2 3140/4885AHR 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.